Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2022/04/042144
CTRI/2022/04/042144
Completed
未知

A randomized trial to evaluate the role of adjuvant basal cisternostomy in traumatic brain injury patients planned for decompressive craniectomy in a tertiary care center in India. - ABC

King Georges Medical University0 sites100 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: O- Medical and Surgical

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: O- Medical and Surgical
Sponsor
King Georges Medical University
Enrollment
100
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 30, 2023
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
King Georges Medical University

Eligibility Criteria

Inclusion Criteria

  • •Patients of age 18 years and above presenting with traumatic brain injury having surgically evacuable lesions and brain is bulging after evacuation of hematoma.

Exclusion Criteria

  • •1\. Hemodynamic instability (polytrauma cases)
  • •2\. Pregnant females
  • •3\. Coagulopathy
  • •4\. Brain stem dysfunction and signs of irreversible brain damage (b/l fixed dilated pupils)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
A study to know the efficacy of adjuvant IgM in reducing mortality of very low birth weight newborns with sepsisHealth Condition 1: P369- Bacterial sepsis of newborn, unspecified
CTRI/2022/09/045566Dr Rinku Saini
Active, not recruiting
Phase 3
Evaluating the potential benefit of adjuvant chemotherapy for small bowel adenocarcinomaSmall bowel adenocarcinomaCancer
ISRCTN15070952Greater Glasgow and Clyde Healthboard and University of Glasgow69
Not yet recruiting
Not Applicable
A study to assess effectiveness of hydrogel and honey in treatment of diabetic foot ulcer among diabetic patients residing in rural areas of nellore
CTRI/2020/12/030103arayana College Of Nursing
Not yet recruiting
Phase 2
Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observatio
NL-OMON50102niversity Hospital Essen30
Active, not recruiting
Phase 1
Comparison of therapy of Merkel Cell Carcinoma (MCC) with Ipilimumab (Yervoy®) or Nivolumab (Opdivo®) versus observation onlycompletely resected Merkel cell carcinomaMedDRA version: 21.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-000043-78-DEniversity of Essen190